Clinical trials and translational research are integral to the care of our patients and crucial to providing the best chance of cure. Neuroscience research provides patients with the best and latest treatments available for complex neurological disorders and diseases. Research identifies and evaluates new treatments to help future children.
At Barrow at Phoenix Children's, this translates into cutting edge care and access to the most promising new options. We collaborate with a number of local, regional and national partners, sharing data with institutions worldwide in the search of the best treatments and cures.
Barrow Neurological Institute at Phoenix Children's is committed to providing excellence in research. Collaborations and strategic partnerships enable us to provide children with access to the best care, diagnostic tools and treatments available.
Research is central to our mission of improving the lives of children with neurological disorders, as it provides us with the knowledge to improve care in the future. Knowledge learned in the laboratory and through clincal research is "translated" back to the bedside to continue to improve upon and advance neuroscience care.
Focus areas in research include:
Biologic Materials Availability Program
The Biologic Materials Availability Program (BMAP) at Phoenix Children’s, under the direction of Jorge Arango, MD, and David Carpenteri, MD, is an initiative aimed to provide investigators with biological materials for research and/or the means to access them.
The program collects a variety of tissues and bio-fluids that are on their vast majority otherwise discarded, these include surplus tissues from anatomic pathology and the clinical laboratory and/or discarding materials accessed through surgery or bedside procedures and devices.
The neuroscientific division of BMAP is the most active area of sample collection and processing. The creation of a cerebrospinal fluid (CSF) bank has made this division a leading entity in research support due to the variety of the CSF collected. The relatively wide spectrum of neurological conditions for which CSF is available has promoted associations with investigators and institutions working with advance molecular techniques, including:
- Micro RNA